ESTRO 2025 - Abstract Book

S1648

Clinical – äediatric tumours

ESTRO 2025

3656

Digital Poster Pediatric nasopharyngeal carcinoma: Data from 2018 to 2023 IMANE I HASSNAOUI 1,2 , Rania R El Gueddari 1,2 , Ngbwa E Edith Tatiana D. 1,2 , Karima K Nouni 1,2 , Amine A Lachgar 1,2 , Hanan H Elkacemi 1,2 , Tayeb T Kebdani 1,2 , Khalid K Hassouni 1,2 1 Radiotherapy, nationale institute of oncology, Rabat, Morocco. 2 medicine, faculty of medecine and pharmacy, Rabat, Morocco Purpose/Objective: Nasopharyngeal Carcinoma is a malignant tumor that unfortunately spares no age group, including children. It is one of the rare pediatric tumors with an epithelial origin. The aim of this study was to determine the short-and long-term results of patients who have been treated by Radiotherapy and Chemotherapy for a nasopharyngeal carcinoma. Material/Methods: The present retrospective study is an experience of the National Institute of Oncology and Pediatric Hematology and Oncology Department at Children's Hospital in Rabat in Morocco in the curative treatment of nasopharyngeal carcinoma 21 patients were treated for non-metastatic nasopharyngeal carcinoma from January 2018 to December 2023. We only included the patients who were histologically and radiology proven nasopharyngeal carcinoma disease. Results: In this study, 80% were male, 20 % were female with a median age of 12 years, extremes between 7 years and 15 years. The revealing signs are cervical adenopathy in90% of the patients, 16 of the patients had an alteration of the general condition with weight loss, and multiple signs were also reported as rhino logical, otological and neurological signs. Diagnostic and extension imagery performed on all patients include anasopharyngeal CT scan, chest X-ray, abdominal ultrasound and bone scan. Only 25% of the patients had a nasopharyngeal IRM, we were able to categorize patients according to the TNM classification. 13 patients had a T4 stage, 8 patients had a T3 stage. Regarding to lymph nodes 85% of the patients had N2 stage. All patients received three courses of neoadjuvant Chemotherapy type bleomycin, epirubicin and cisplatin. Patients were irradiated with a Volumetric Modulated Arc Therapy at a dose between 68 Gy and 70 Gy. Concomitant chemotherapy based on Cisplatin was administered to all patients. 90% of the patient reported nausea and emesis because of Chemotherapy. Regarding to hematologic toxicity, 20 % reported anemia, 30 % developed a neutropenia. Radiotherapy, onthe other hand, 20% of the patient related a trismus, 50 % had hypoacusis and 2 patients presented a total deafness and all of the patients had a Radiomucite Grade 3 or 4, 3 patients reported a growth restriction and one girl reported having an amenorrhea. Currentely, 17 patients are alive with a complete remission, 3 patients died and two patients were lost to follow-up. Conclusion: Pediatric nasopharyngeal carcinoma is unfortunately often diagnosed at an advanced stage. Thanks to the new techniques of radiotherapy and molecules of chemotherapy, therapeutic benefits have been improved, resulting in longer life expectancy and increased quality of life.

Keywords: Nasopharyngeal Carcinoma – Pediatric